Old Web
English
Sign In
Acemap
>
authorDetail
>
Patricia A Lorenzini
Patricia A Lorenzini
Janssen Pharmaceutica
Medicine
EGFR Tyrosine Kinase Inhibitors
Exon
poor prognosis
in patient
2
Papers
42
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic Non‒Small-Cell Lung Cancer: Brief Report on a Randomized, Open-label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
2020
Rathi N. Pillai
Suresh S. Ramalingam
Meena Thayu
Patricia A Lorenzini
Diana A. Alvarez Arias
Christopher Moy
Natalie A. Hutnick
Roland Elmar Knoblauch
Huaibao Feng
Colleen Kane
Leora Horn
M. Reck
Santiago Ponce
Show All
Source
Cite
Save
Citations (0)
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
2020
Journal of Clinical Oncology
Keunchil Park
Thomas John
Sang-We Kim
Jong Seok Lee
Catherine A. Shu
Dong-Wan Kim
Santiago Viteri Ramirez
Alexander I. Spira
Joshua K. Sabari
Ji Youn Han
José Manuel Trigo
Chee Khoon Lee
Ki Hyeong Lee
Nicolas Girard
Patricia A Lorenzini
John Xie
Amy Roshak
Meena Thayu
Roland Elmar Knoblauch
Byoung Chul Cho
Show All
Source
Cite
Save
Citations (42)
1
map